Faecal calprotectin and lactoferrin as markers of acute radiation proctitis: a pilot study of eight stool markers

References

• Safwat A, Bentzen SM, Turesson I, Hendry JH. Deterministic rather than stochastic factors explain most of the variation in the expression of skin telangiectasia after radiotherapy. Int J Radiat Oncol Biol Phys 2002;52:198–204.
   PubMed Web of Science ®Google Scholar
• Richter KK, Wang J, Fagerhol MK, Hauer-Jensen M. Radiation-induced granulocyte transmigration predicts development of delayed structural changes in rat intestine. Radiother Oncol 2001; 59:81–5.
   Google Scholar
• Hovdenak N, Fajardo LF, Hauer-Jensen M. Acute radiation proctitis: a sequential clinicopathologic study during pelvic radiotherapy. Int J Radiat Oncol Biol Phys 2000;48:1111–7.
   Google Scholar
• Roseth AG, Fagerhol MK, Aadland E, Schjonsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992;27:793–8.
   PubMed Web of Science ®Google Scholar
• Ton H, Brandsnes O, Dale S, Holtlund J, Skuibina E, Schjonsby H, et al. Improved assay for fecal calprotectin. Clin Chim Acta 2000;292:41–54.
   PubMed Web of Science ®Google Scholar
• Sugi K, Saitoh O, Hirata I, Katsu K. Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol 1996; 91:927–34.
   PubMed Web of Science ®Google Scholar
• Uchida K, Matsuse R, Tomita S, Sugi K, Saitoh O, Ohshiba S. Immunochemical detection of human lactoferrin in feces as a new marker for inflammatory gastrointestinal disorders and colon cancer. Clin Biochem 1994;27:259–64.
   PubMed Web of Science ®Google Scholar
• Miyoshi H, Ohshiba S, Asada S, Hirata I, Uchida K. Immunological determination of fecal hemoglobin and transferrin levels: a comparison with other fecal occult blood tests. Am J Gastroenterol 1992;87:67–73.
   Google Scholar
• Saitoh O, Matsumoto H, Sugimori K, Sugi K, Nakagawa K, Miyoshi H, et al. Intestinal protein loss and bleeding assessed by fecal hemoglobin, transferrin, albumin, and alpha-1-antitrypsin levels in patients with colorectal diseases. Digestion 1995;56:67–75.
   PubMed Web of Science ®Google Scholar
• Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992;339 (8785):89–91.
   Google Scholar
• Saiki T, Mitsuyama K, Toyonaga A, Ishida H, Tanikawa K. Detection of pro- and anti-inflammatory cytokines in stools of patients with inflammatory bowel disease. Scand J Gastroenterol 1998;33:616–22.
   Google Scholar
• Waage A. Production and clearance of tumor necrosis factor in rats exposed to endotoxin and dexamethasone. Clin Immunol Immunopathol 1987;45:348–55.
   PubMedGoogle Scholar
• Gould SR. Prostaglandins, ulcerative colitis, and sulphasalazine [Letter]. Lancet 1975;2 (7942):988.
   PubMed Web of Science ®Google Scholar
• Cole AT, Slater K, Sokal M, Hawkey CJ. In vivo rectal inflammatory mediator changes with radiotherapy to the pelvis. Gut 1993;34:1210–4.
   PubMed Web of Science ®Google Scholar
• Lauritsen K, Laursen LS, Bukhave K, Rask-Madsen J. Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis. Gastroenterology 1986;91: 837–44.
   Google Scholar
• Bischoff SC, Grabowsky J, Manns MP. Quantification of inflammatory mediators in stool samples of patients with inflammatory bowel disorders and controls. Dig Dis Sci 1997;42:394–403.
   Google Scholar
• Fagerhol MK. Calprotectin, a faecal marker of organic gastrointestinal abnormality. Lancet 2000;356 (9244):1783–4.
   PubMed Web of Science ®Google Scholar
• Johne B, Fagerhol MK, Lyberg T, Prydz H, Brandtzaeg P, Naess-Andresen CF, et al. Functional and clinical aspects of the myelomonocyte protein calprotectin. Mol Pathol 1997;50:113–23.
   Google Scholar
• Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and cal-protectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 1999;34: 50–4.
   Google Scholar
• Bunn SK, Bisset WM, Main MJ, Gray ES, Olson S, Golden BE. Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001;33:14–22.
   PubMed Web of Science ®Google Scholar
• Roseth AG, Aadland E, Jahnsen J, Raknerud N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997;58:176–80.
   PubMed Web of Science ®Google Scholar
• Kane SV, Sandborn WJ, Rufo PA, Zholudev A, Boone J, Lyerly D, et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 2003;98: 1309–14.
   PubMed Web of Science ®Google Scholar
• Isaksen B, Fagerhol MK. Calprotectin inhibits matrix metalloproteinases by sequestration ofzinc. Mol Pathol 2001;54:289–92.
   PubMedGoogle Scholar
• Hovdenak N, Wang J, Sung CC, Kelly T, Fajardo LF, Hauer-Jensen M. Clinical significance of increased gelatinolytic activity in the rectal mucosa during external beam radiation therapy of prostate cancer. Int J Radiat Oncol Biol Phys 2002;53:919–27.
   Google Scholar
• Sohnle PG, Hunter MJ, Hahn B, Chazin WJ. Zinc-reversible antimicrobial activity of recombinant calprotectin (migration inhibitory factor-related proteins 8 and 14). J Infect Dis 2000; 182:1272–5.
   PubMed Web of Science ®Google Scholar
• Salminen E, Elomaa I, Minkkinen J, Vapaatalo H, Salminen S. Preservation of intestinal integrity during radiotherapy using live Lactobacillus acidophilus cultures. Clin Radiol 1988;39:435–7.
   Google Scholar
• Haro H, Crawford HC, Fingleton B, Shinomiya K, Spengler DM, Matrisian LM. Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption. J Clin Invest 2000;105:143–50.
   PubMed Web of Science ®Google Scholar
• Conneely OM. Antiinflammatory activities of lactoferrin. J Am Coll Nutr 2001;20 Suppl 5:389S–395S.
   Google Scholar
• Togawa J, Nagase H, Tanaka K, Inamori M, Umezawa T, Nakajima A, et al. Lactoferrin reduces colitis in rats via modulation of the immune system and correction of cytokine imbalance. Am J Physiol Gastrointest Liver Physiol 2002;283: G187–G95.
   Web of Science ®Google Scholar
• Kerkhoff C, Klempt M, Kaever V, Sorg C. The two calciumbinding proteins, S100A8 and S100A9, are involved in the metabolism of arachidonic acid in human neutrophils. J Biol Chem 1999;274:32672–9.
   PubMed Web of Science ®Google Scholar
• Steinauer KK, Gibbs I, Ning S, French JN, Armstrong J, Knox SJ. Radiation induces upregulation of cyclooxygenase-2 (COX-2) protein in PC-3 cells. Int J Radiat Oncol Biol Phys 2000;48:325–8.
   PubMed Web of Science ®Google Scholar
• Khan AM, Birk JW, Anderson JC, Georgsson M, Park TL, Smith CJ, et al. A prospective randomized placebo-controlled double-blinded pilot study of misoprostol rectal suppositories in the prevention of acute and chronic radiation proctitis symptoms in prostate cancer patients. Am J Gastroenterol 2000;95:1961–6.
   PubMed Web of Science ®Google Scholar
• Denham JW, O’Brien PC, Dunstan RH, Johansen J, See A, Hamilton CS, et al. Is there more than one late radiation proctitis syndrome? Radiother Oncol 1999;51:43–53.
   PubMed Web of Science ®Google Scholar
• Schultheiss TE, Lee WR, Hunt MA, Hanlon AL, Peter RS, Hanks GE. Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 1997;37:3–11.
   PubMed Web of Science ®Google Scholar
• Hovdenak N, Karlsdottir A, Sorbye H, Dahl O. Profiles and time course of acute radiation toxicity symptoms during conformal radiotherapy for cancer of the prostate. Acta Oncol 2003; 42: 741–8.
   PubMed Web of Science ®Google Scholar